Effects of Coenzyme Q10 Supplement on Cardiovascular Risk Factors in Subjects at High Risk of Metabolic Syndrome

Last updated: July 11, 2024
Sponsor: Tian Zezhong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Vascular Diseases

Diabetes Prevention

Metabolic Syndrome

Treatment

coenzyme Q10

placebo

Clinical Study ID

NCT06506630
20240703
  • Ages 30-90
  • All Genders

Study Summary

This study aims to evaluate the ameliorating effect of coenzyme Q10 supplementation on cardiovascular risk factors in high risk population for metabolic syndrome, including blood lipid metabolism, insulin resistance, blood pressure regulation, platelet function, endothelial function, cardiorespiratory fitness and muscle function.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Metabolic syndrome or high-risk groups with metabolic syndrome are defined assubjects with metabolic syndrome according to the International Diabetes Federation (IDF) Chinese Adult Criteria, and high-risk groups are defined as those who meet atleast two MetS risk factors. The specific criteria are as follows:
  1. Aged 30-90 years old;

  2. Two or more of following are acceptable:

  3. Abdominal obesity (central obesity): waist circumference >=90 cm for men and >=80cm for women;

  4. Hyperglycemia: fasting blood glucose ≥ 5.6mmol/L or taking hypoglycemic drugs;

  5. Hypertension: systolic blood pressure >=130mmHg and (or) diastolic bloodpressure >=85mmHg or taking blood pressure medications;

  6. Fasting TG>=1.70mmol/L or taking antihyperlipidemic drug;

  7. Fasting HDL-C<1.04 mmol/L for men, <1.29 mmol/L for women or takingantihyperlipidemic drug; 3) Sign informed consent and insist on participatingin the research.

Exclusion

Exclusion Criteria:

  1. Take drugs/dietary supplements, such as aspirin, fish oil and etc., that affectplatelet function in recently six months; 2) blood system disease or infection;
  2. Blood pressure >=160/100mmHg; 4) Low platelet count (whole bloodplatelet<100 x 10^9/mL); 5) Abnormal hemoglobin (male <120g/L, female <110g/L);
  3. Low hematocrit (male <40%, female <37%); 7) Prothrombin time (PT) is outsidethe normal reference range; 8) Pregnant women or nursing mothers; 9) Abnormalmenstrual cycle, taking birth control pills or hormone replacement therapy; 10)Gastric ulcer, liver or kidney dysfunction.

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: coenzyme Q10
Phase:
Study Start date:
September 11, 2023
Estimated Completion Date:
December 30, 2024

Connect with a study center

  • School of Public Health (Shenzhen), Sun Yat-sen University

    Shenzhen, 518107
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.